COVID-19: immunopathology and its implications for therapy
- PMID: 32273594
- PMCID: PMC7143200
- DOI: 10.1038/s41577-020-0308-3
COVID-19: immunopathology and its implications for therapy
Abstract
Severe coronavirus disease 2019 (COVID-19) is characterized by pneumonia, lymphopenia, exhausted lymphocytes and a cytokine storm. Significant antibody production is observed; however, whether this is protective or pathogenic remains to be determined. Defining the immunopathological changes in patients with COVID-19 provides potential targets for drug discovery and is important for clinical management.
Conflict of interest statement
The author declares no competing interests.
Comment in
-
COVID-19: room for treating T cell exhaustion?Crit Care. 2020 May 15;24(1):229. doi: 10.1186/s13054-020-02960-0. Crit Care. 2020. PMID: 32414395 Free PMC article. No abstract available.
-
COVID-19: collaboration will keep us ahead of the curve.Intern Med J. 2020 Jul;50(7):784-786. doi: 10.1111/imj.14888. Intern Med J. 2020. PMID: 32656972 Free PMC article. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
